CAMBRIDGE, Mass., July 12, 2011 /PRNewswire/ -- GNS Healthcare, Inc. (GNS) is collaborating with the National Cancer Institute (NCI) to accelerate lung cancer research with a supercomputing platform that can rapidly uncover cause-and-effect mechanisms hidden in huge data sets assembled from imaging, genetics, pathology, and other areas. The results could help predict which patients will respond to a given treatment.
GNS will analyze NCI data from the laboratory of Terry van Dyke, Ph.D., Director of the Center for Advanced Preclinical Research (CAPR) at NCI. These data were generated from genetically modified mouse models of non-small cell lung cancer (NSCLC).
This collaboration will utilize GNS's supercomputer-driven REFS(TM) platform to build computer models of NSCLC in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms of NSCLC. The goal is to identify biomarkers and biological mechanisms that will lead to better matching of drugs to patients and new effective drugs in NSCLC.
"GNS is excited to be deploying our supercomputer-driven REFS(TM) platform to enable the maximal extraction of actionable knowledge from the rich lung cancer datasets generated by the NCI," said GNS Executive Vice President and Co-Founder Dr. Iya Khalil. "Combined with the expertise of our NCI colleagues in lung cancer biology and in designing powerful experiments to uncover its key mechanisms, we are creating the opportunity to provide better outcomes for lung cancer patients."
The data utilized in the collaboration will include data from the experimental assessment of transcriptomic and MRI data relating to NSCLC induction, regression and combination drug treatments. Starting from this data, GNS will utilize the REFS(TM) platform to reverse-engineer network models from the data that connect drug doses to transcriptional and imaging measurement networks to endpoi
|SOURCE GNS Healthcare, Inc.|
Copyright©2010 PR Newswire.
All rights reserved